Type I Chemotype (THC-Dominant)

What Type I chemotype is

Type I is a cannabis chemotype—a plant that produces predominantly THC and very little CBD in its mature flowers. The chemotype system was proposed by Small and Beckstead in 1973 after they examined the cannabinoid content of hundreds of cannabis accessions and found that plants sorted into distinct groups based on the ratio of THC to CBD ^[1]. They defined three core chemotypes:

• Type I: THC-dominant, low CBD (THC:CBD >> 1)
• Type II: roughly balanced THC and CBD
• Type III: CBD-dominant, low THC (hemp-type)

Later work identified Type IV (CBG-dominant) and Type V (essentially cannabinoid-free fiber hemp) ^[2].

The chemotype system is based on the plant's cannabinoid chemistry, not on morphology (shape, height, leaf width) or terpene profile. Two plants that look completely different—one short and bushy, one tall and lanky—can both be Type I if they produce high THC and low CBD. Similarly, a Type I plant can have any dominant terpene profile. Strong evidence Chemotype is also independent of the marketing categories "indica," "sativa," and "hybrid," which have no scientific basis in cannabis genetics.

Genetics: the enzyme locus

Type I plants are Type I because of their genes encoding two closely related enzymes: THCA synthase and CBDA synthase. These enzymes convert CBGA (the common precursor to all major cannabinoids) into either THCA (which decarboxylates to THC when heated) or CBDA (which becomes CBD). Strong evidence

De Meijer and colleagues demonstrated in 2003 that the THC:CBD ratio segregates in crosses as if controlled by a single genetic locus with two codominant alleles, which they named B_T (encoding THCA synthase) and B_D (encoding CBDA synthase) ^[3].

• A plant homozygous B_T/B_T produces almost entirely THCA—this is Type I.
• A plant homozygous B_D/B_D produces almost entirely CBDA—this is Type III.
• A heterozygote (B_T/B_D) produces roughly equal amounts of both—this is Type II. Strong evidence

More recent genomic studies have shown that the THCAS and CBDAS genes sit in a complex, repeat-rich region of the cannabis genome, and some Type I plants actually carry non-functional CBDAS pseudogenes rather than a functional alternative allele ^[4]. Despite this genomic complexity, the simple B_T/B_T ≈ Type I prediction remains reliable for practical breeding and cultivation.

Where Type I is found

Essentially all commercial cannabis flower sold in adult-use and medical dispensaries—in the United States, Canada, the Netherlands, Germany, Thailand, and other legal or tolerated markets—is Type I. Strong evidence

Testing of legal-market flower from Washington, Colorado, and California shows a consistent mean THC concentration around 18–22% with CBD typically below 0.5% ^[5]. Decades of seizure analysis by ElSohly's laboratory at the University of Mississippi revealed a steady trend since the 1970s toward higher-THC Type I material and away from the more balanced Type II profiles that were more common in earlier decades ^[6].

Type I is not confined to one region or landraces of origin. Modern Type I cultivars descend from a global mix of cannabis populations—Afghan hashish varieties, Mexican and Colombian sativas, Thai stick, South African Durban—most of which were themselves Type I or Type II before selective breeding intensified the shift toward pure Type I.

Effects and therapeutic use

What knowing a plant is Type I tells you—and what it doesn't:

Knowing a flower is Type I reliably predicts that it will produce intoxication. It does not predict the character, intensity, or side-effect profile of that intoxication. Whether you experience euphoria or anxiety, relaxation or racing thoughts, creative clarity or cognitive fog depends on total THC dose, individual tolerance and metabolism, the terpene and minor-cannabinoid profile, route of administration (smoking, vaping, oral ingestion), and your mental state and environment going in.

Controlled research:

Human controlled trials confirm that THC-dominant cannabis (Type I) produces the expected acute effects: intoxication, impaired short-term memory, altered time perception, increased heart rate, and—at higher doses—anxiety and psychotomimetic (psychosis-like) effects in some users ^[7]. Strong evidence

When Type I flower is compared to Type II (balanced THC:CBD) at equivalent THC doses, Type I is more likely to produce anxiety and paranoia. This suggests that CBD provides a buffering or anxiolytic effect, though the magnitude and mechanism of this interaction remain debated ^[8]. Strong evidence

Medical applications:

Type I flower and THC-containing extracts are used clinically for chronic pain, chemotherapy-induced nausea and vomiting, appetite stimulation, and spasticity related to multiple sclerosis. The evidence base varies by indication. The strongest evidence supports THC for chemotherapy-related nausea and MS-related spasticity. Evidence for chronic pain and sleep is weaker and more mixed ^[9]. Strong evidence

No reliable evidence currently supports using Type I cannabis as a treatment for conditions like cancer, autism, or inflammatory bowel disease, despite popular claims. Clinical trial data, when available, do not support cure or reversal claims.

Common cultivars and strains

Nearly every named cannabis cultivar sold in dispensaries is Type I. Rather than enumerate them—the list is long and ever-growing—it is more useful to identify the exceptions.

Type II (balanced THC:CBD) cultivars:

• Cannatonic
• Harlequin
• Pennywise
• Remedy

Type III (CBD-dominant) cultivars:

• Charlotte's Web
• ACDC
• Ringo's Gift
• Cannatol

Type IV (CBG-dominant, rare):

• Certain Bediol genetics
• Italian medical breeding lines

Type I (THC-dominant) cultivars—the vast majority, including:

• OG Kush
• Gorilla Glue #4
• Blue Dream
• Girl Scout Cookies
• Wedding Cake
• Runtz
• Zkittlez
• Sour Diesel
• Northern Lights

A practical rule: If a laboratory certificate of analysis (COA) shows THC in the range of 15–30% and CBD below 1%, you have a Type I sample, regardless of whether the product is marketed as "indica," "sativa," or "hybrid." Strong evidence

Related chemotypes and classification systems

Other cannabinoid chemotypes:

• Type II Chemotype: Roughly 1:1 to 2:1 THC:CBD ratio. Heterozygous (B_T/B_D) at the B locus. Produces both THCA and CBDA in substantial amounts.
• Type III Chemotype: CBD-dominant (CBD:THC >> 1). Homozygous B_D/B_D. Includes industrial hemp and medical CBD cultivars.
• Type IV Chemotype: CBG-dominant. Requires mutations downstream of CBGA that block both THCA and CBDA synthase activity, diverting CBGA into CBG.
• Type V Chemotype: Essentially zero major cannabinoids. Fiber hemp phenotype; used for seed and stem production.

Important distinctions:

Chemotype is orthogonal (independent) to the popular "indica vs. sativa" marketing categories and to the plant's terpene profile. A Type I plant can be dominated by myrcene, limonene, terpinolene, caryophyllene, or any other major terpene. A "sativa" label tells you nothing about chemotype, and a high myrcene content does not predict whether a plant is Type I or Type III. For more on the limitations of the indica/sativa framework, see The Indica/Sativa Myth. For information on terpene classification, see Chemotype.

Sources

How this page was made

Related

• Chemotype — Plant classification by cannabinoid ratio, not genetics or morphology.
• Genotype — The complete DNA blueprint a plant inherits from its parents.
• The Indica/Sativa Myth — The popular classification system contradicts genetics, chemistry, and controlled research...
• Type II Chemotype (Mixed THC/CBD Cannabis) — Cannabis plants with roughly equal THC and CBD, determined by genetics at the cannabinoid...